Primary central nervous system lymphoma MRI

Primary central nervous system lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Primary Central Nervous System Lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Primary central nervous system lymphoma MRI On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Primary central nervous system lymphoma MRI All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Primary central nervous system lymphoma MRI
CDC on Primary central nervous system lymphoma MRI
Primary central nervous system lymphoma MRI in the news
Blogs on Primary central nervous system lymphoma MRI
Directions to Hospitals Treating Primary central nervous system lymphoma
Risk calculators and risk factors for Primary central nervous system lymphoma MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

MRI

MRI usually shows multiple (1 to 3) 3- to 5-cm ring-enhancing lesions in almost any location, but usually deep in the white matter. The major differential diagnosis is cerebral toxoplasmosis, which is also prevalent in AIDS patients and also presents with a ring-enhanced lesion, although the contrast enhancement is more pronounced in toxoplasmosis and it presents with more lesions.

MRI component	Findings
T1	Typically hypointense to white matter
T2	Variable Majority are iso- to hypointense Isointense: 33% Hypointense: 20% Hyperintense: 15-47%, more common in tumors with necrosis
T1 with gadolinium contrast	Typical high grade tumors demonstrate intense homogeneous enhancement while low-grade tumors have absent to moderate enhancement Peripheral ring enhancement may be observed in immunocompromised patients (HIV/AIDS)
Diffusion-weighted imaging/apparent diffusion coefficient (DWI/ADC)	Typical restricted diffusion More restricted diffusion and lower ADC values compared to high-grade gliomas and metastases

References

Template:WikiDoc Sources